Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.

doi:10.1007/s00401-015-1403-6

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.

Acta neuropathologica - 1 Apr 2015

van Thuijl Hinke F, Mazor Tali, Johnson Brett E, Fouse Shaun D, Aihara Koki, Hong Chibo, Malmström Annika, Hallbeck Martin, Heimans Jan J, Kloezeman Jenneke J, Stenmark-Askmalm Marie, Lamfers Martine L M, Saito Nobuhito, Aburatani Hiroyuki, Mukasa Akitake, Berger Mitchell S, Söderkvist Peter, Taylor Barry S, Molinaro Annette M, Wesseling Pieter, Reijneveld Jaap C, Chang Susan M, Ylstra Bauke, Costello Joseph F

Abstract excerpt

Temozolomide (TMZ) increases the overall survival of patients with glioblastoma (GBM), but its role in the clinical management of diffuse low-grade gliomas (LGG) is still being defined. DNA hypermethylation of the O (6) -methylguanine-DNA methyltransferase (MGMT) promoter is associated with an improved response to TMZ treatment, while inactivation of the DNA mismatch repair (MMR) pathway is associated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dacarbazine

Share to DNA Modification Methylases

Share to DNA Repair Enzymes

Share to Glioma

Share to Receptors, Immunologic

Share to Statistics, Nonparametric

Share to Temozolomide

Source

Open in PubMed Open full text

Identifiers

PMID: 25724300
DOI: 10.1007/s00401-015-1403-6
PMCID: PMC4482618

Genes

MGMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.PMID 25724300Read ↗

MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrenceSemantic proximity Read ↗

A multifaceted review of temozolomide resistance mechanisms in glioblastoma beyond O-6-methylguanine-DNA methyltransferaseSemantic proximity Read ↗

DNA methylation remodeling in temozolomide resistant recurrent glioblastoma: comparing epigenetic dynamics in vitro and in vivoSemantic proximity Read ↗

Variations in DNA Repair Genes and Intratumoral Genetic Heterogeneity in Temozolomide-Resistant Glioblastoma.Semantic proximity Read ↗

Concurrent hypermethylation of DNMT1, MGMT and EGFR genes in progression of gliomas.Semantic proximity Read ↗

Glioblastoma recurrence and the role of MGMT promoter methylationSemantic proximity Read ↗

Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent GliomaSemantic proximity Read ↗

Glioblastoma Recurrence and the Role of O<sup>6</sup>-Methylguanine–DNA Methyltransferase Promoter MethylationSemantic proximity Read ↗

The Temozolomide Mutational Signature: Mechanisms, Clinical Implications, and Therapeutic Opportunities in Primary Brain Tumor Management.Semantic proximity Read ↗

Temozolomide-associated hypermutation in gliomas.Semantic proximity Read ↗

The Changes in MGMT Promoter Methylation Status in Initial and Recurrent GlioblastomasSemantic proximity Read ↗

Mechanisms of temozolomide resistance in glioblastoma - a comprehensive reviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.